Table 3.

Presence of fatty liver at baseline and follow-up in Lean, Ob_Sen and Ob_Res.

Presence of Fatty Liver (Baseline to Follow-Up) *	Study Group
	Lean (n, % of Group)	ObSen (n, % of Group)	ObRes (n, % of Group)
Stable Absence (n = 14)	7 (64%)	5 (56%)	2 (12%)
Gain of fatty liver (n = 5)	2 (18%)	2 (22%)	1 (6%)
Loss of fatty liver (n = 2)	1 (9%)	0 (0%)	1 (6%)
Stable Presence (n = 16)	1 (9%)	2 (22%)	13 (76%)
Total (n = 37)	11 (100%)	9 (100%)	17 (100%)

Paired liver fat measurements were available for a sub-cohort of 37 individuals who had CT and MRS at baseline and follow-up, respectively. * Presence of fatty liver determined by a CT value of <54.2 Hu at baseline and MRS > 1.8% at follow-up, as described by van Werven et al. [21]. Terminology: Stable Absence: Fatty liver absent at baseline and follow-up; Gain of fatty liver: Fatty liver absent at baseline but present at follow-up; Loss of fatty liver: Fatty liver present at baseline but absent at follow-up; Stable Presence: Fatty liver present at baseline and follow-up.